|
|
|
Aeon Biopharma inc (NYSEAMER: AEON) |
|
AEON's Market share relative to its competitors, as of Q1 2025
As of Q1 2025 (Revenue in Millions of $)
Date modified: 2025-05-18T10:07:43+00:00
|
Select the Relationship:
|
|
Select the Category:
|
|
| COMPANY NAME |
REVENUES
12 Months Ending
Q1 2025 |
MARKET SHARE
12 Months
Q1 2025 |
MARKET SHARE
MRQ
Q1 2025 |
MARKET SHARE
A Quarter Before
Q4 2024 |
| Aeon Biopharma inc |
0.00 |
0.00% |
0.00 % |
0.00 % |
| Abbvie Inc |
57,367.00 |
33.28% |
32.58% |
33.85% |
| Eli Lilly And Company |
49,003.20 |
28.43% |
31.08% |
30.33% |
| Viatris Inc |
14,330.20 |
8.31% |
7.95% |
7.91% |
| Vertex Pharmaceuticals Inc |
11,099.70 |
6.44% |
6.76% |
6.53% |
| Biogen Inc |
9,816.40 |
5.69% |
5.94% |
5.50% |
| Bausch Health Companies Inc |
9,731.00 |
5.64% |
5.52% |
5.74% |
| Jazz Pharmaceuticals Plc |
4,064.81 |
2.36% |
2.19% |
2.44% |
| Horizon Therapeutics Public Limited Company |
3,643.45 |
2.11% |
2.31% |
1.87% |
| Biomarin Pharmaceutical Inc |
2,950.23 |
1.71% |
1.82% |
1.68% |
| Adhera Therapeutics Inc |
2,732.01 |
1.58% |
0.00% |
0.00% |
| Royalty Pharma Plc |
2,263.85 |
1.31% |
1.39% |
1.33% |
| Alkermes Plc |
1,513.77 |
0.88% |
0.75% |
0.96% |
| Acadia Pharmaceuticals Inc |
996.28 |
0.58% |
0.60% |
0.58% |
| Biohaven Ltd |
859.68 |
0.50% |
0.00% |
0.00% |
| Kiniksa Pharmaceuticals International Plc |
481.17 |
0.28% |
0.34% |
0.27% |
| Axsome Therapeutics Inc |
449.36 |
0.26% |
0.30% |
0.37% |
| Galapagos Nv |
268.49 |
0.16% |
0.16% |
0.00% |
| Vanda Pharmaceuticals Inc |
201.35 |
0.12% |
0.12% |
0.12% |
| Amylyx Pharmaceuticals Inc |
196.49 |
0.11% |
0.00% |
0.00% |
| Gossamer Bio Inc |
124.59 |
0.07% |
0.02% |
0.02% |
| Theravance Biopharma inc |
65.27 |
0.04% |
0.04% |
0.04% |
| Aquestive Therapeutics Inc |
54.23 |
0.03% |
0.02% |
0.03% |
| Sage Therapeutics Inc |
47.40 |
0.03% |
0.03% |
0.03% |
| Mereo Biopharma Group Plc |
36.46 |
0.02% |
0.00% |
0.00% |
| Bicycle Therapeutics Plc |
25.72 |
0.01% |
0.02% |
0.01% |
| Medicure Inc |
16.78 |
0.01% |
0.01% |
0.00% |
| Xenon Pharmaceuticals Inc |
13.17 |
0.01% |
0.02% |
0.00% |
| Karuna Therapeutics Inc |
11.29 |
0.01% |
0.00% |
0.00% |
| Cogent Biosciences Inc |
7.87 |
0.00% |
0.00% |
0.00% |
| Dianthus Therapeutics Inc |
6.52 |
0.00% |
0.00% |
0.00% |
| Qualigen Therapeutics Inc |
4.79 |
0.00% |
0.00% |
0.00% |
| Ngm Biopharmaceuticals Inc |
4.42 |
0.00% |
0.00% |
0.00% |
| Infinity Pharmaceuticals Inc |
2.57 |
0.00% |
0.00% |
0.00% |
| Aptinyx Inc |
1.75 |
0.00% |
0.00% |
0.00% |
| Comera Life Sciences Holdings Inc |
1.10 |
0.00% |
0.00% |
0.00% |
| Timber Pharmaceuticals Inc |
0.88 |
0.00% |
0.00% |
0.00% |
| Nexttrip Inc |
0.88 |
0.00% |
0.00% |
0.00% |
| Clene Inc |
0.35 |
0.00% |
0.00% |
0.00% |
| Gain Therapeutics inc |
0.21 |
0.00% |
0.00% |
0.00% |
| Nascent Biotech Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Cassava Sciences Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Cytodyn inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Xtl Biopharmaceuticals Ltd |
0.00 |
0.00% |
0.00% |
0.00% |
| Dice Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Ventyx Biosciences Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Azitra Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Acelyrin Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Nexien Biopharma Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Protokinetix Incorporated |
0.00 |
0.00% |
0.00% |
0.00% |
| Acer Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Cohbar Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Galecto Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Protagenic Therapeutics Inc new |
0.00 |
0.00% |
0.00% |
0.00% |
| Satsuma Pharmaceuticals Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Connect Biopharma Holdings Limited |
0.00 |
0.00% |
0.00% |
0.06% |
| Climb Bio Inc |
0.00 |
0.00% |
0.02% |
0.00% |
| Opus Genetics Inc |
0.00 |
0.00% |
0.01% |
0.00% |
| Calcimedica Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Edesa Biotech Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Longboard Pharmaceuticals Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Arrivent Biopharma inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Contineum Therapeutics Inc |
0.00 |
0.00% |
0.00% |
0.00% |
| Os Therapies Incoporated |
0.00 |
0.00% |
0.00% |
0.00% |
| Biostax Corp |
0.00 |
0.00% |
0.00% |
0.00% |
| SUBTOTAL |
172,394.68 |
100% |
40,953.30 |
100% |
AEON's Market share relative to its competitors, as of Q1 2025 within the Major Pharmaceutical Preparations Industry
As of Q1 2025
| COMPANY NAME |
MARKET SHARE
12 Months Ending
Q1 2025 |
MARKET SHARE
12 Months Ending
Q4 2024 |
MARKET SHARE
MRQ
Q1 2025 |
MARKET SHARE
Q4 2024 |
| Aeon Biopharma inc |
0.00% |
0.00% |
0.00 % |
0.00 % |
| SUBTOTAL |
100% |
100% |
100% |
100% |
AEON's Market share relative to its competitors, as of Q1 2025 within the Healthcare Sector
As of Q1 2025
Note: Market share is calculated based on total revenue. To get a more accurate picture of Aeon Biopharma inc's market divisions, geographic dispersion, segments, products, and services, visit Aeon Biopharma inc's Business Segment. The list includes publicly traded companies only. More information about the sources of this report can be found here. |
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
